Predict your next investment

Incanthera company logo
Corporation
HEALTHCARE | Biotechnology
incanthera.com

See what CB Insights has to offer

Stage

Series A - II | Alive

Total Raised

$4.66M

Last Raised

$1.98M | 7 yrs ago

About Incanthera

Incanthera is an oncology company with a unique pipeline of technologies that target tumors. The lead cancer therapeutic opportunity is a new chemical entity called ICT2588, which has been designed to attack all forms of solid tumors while leaving healthy tissue unharmed.

Incanthera Headquarter Location

Suite 315, Liverpool Science Park IC2 146 Brownlow Hill

Liverpool, England, L3 5RF,

United Kingdom

0151 331 5100

Latest Incanthera News

Incanthera files trademark applications for anti skin cancer sun cream

Sep 27, 2021

Incanthera files trademark applications for anti skin cancer sun cream “We continue to make good progress in discussions with our two prioritised partners," said chairman Tim McCarthy The cream is a treatment of solar keratosis and the prevention of skin cancers Incanthera plc ( AQSE:INC ) has filed two trademark names for the commercial use of its skin cancer formulation, currently identified as Sol. The specialist dermatology company said it filed UK trademark applications to register the signs ACTINOMOD and ACTINODERM on Tuesday and Wednesday last week. The applications will now be examined by the UK trade marks office (UKIPO). Incanthera said this was in line with the ongoing progression of its commercialisation goals for its innovative skin cancer technology formulation. Meanwhile, management were said to be continuing to make positive progress on discussions with two global companies for the potential license of its formulation for the treatment of actinic keratosis and prevention of skin cancer. Chairman Tim McCarthy said: “As our licencing discussions progress, the filing of these two trademark names will allow us to look at various branding and marketing opportunities in readiness for next steps. “We continue to make good progress in discussions with our two prioritised partners." Quick facts: Incanthera plc

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Incanthera

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Incanthera is included in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

5,880 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Incanthera Patents

Incanthera has filed 10 patents.

The 3 most popular patent topics include:

  • Prodrugs
  • Experimental cancer drugs
  • Monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/1/2018

2/9/2021

Prodrugs, Experimental cancer drugs, Monoclonal antibodies, Transcription factors, Clusters of differentiation

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/1/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

2/9/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Prodrugs, Experimental cancer drugs, Monoclonal antibodies, Transcription factors, Clusters of differentiation

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.